DOI: 10.1111/dom.15306 [Google Scholar] Pyke C, Heller RS, Kirk RK, Orskov C, Reedtz-Runge S, Kaastrup P, et al
Healthcare regulators, including the UKs MHRA and NICE, have carefully reviewed the evidence and continue to endorse GLP-1 receptor agonists, provided patients and prescribers remain aware of the very small potential risk and take appropriate precautions
Understanding the relationship between GLP-1 medications and erectile function requires consideration of underlying conditions, concurrent medications, and other contributing factors
A recent study conducted on 41 diabetic patients demonstrated that exposure to the GLP-1 RA dulaglutide over a 48-week period was associated with a substantial decrease in non-butyrate-producing Firmicutes (e.g., Ruminococcus and Blautia ), accompanied by an increase in Bacteroides, Lactobacillus , and Prevotella (74)
OMEGA-3 Supports heart and metabolic health